🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with data suggesting more than 82 million new cases annually. Particularly high rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the face of growing infection rates, the spread of superbugs and the very limited treatment choices presently on offer.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the management of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Results and Global Access

As per findings published in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an comparable level with the typical regimen, which uses two antibiotics. The trial involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed optimism. The availability of a single-dose, oral treatment like this is described as a "game-changer" for managing the epidemic. This is deemed essential to reduce the burden of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.